QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2018, 卷号: Vol.13 No.10, 页码: 1539-1548 作者:  Wu, Yi-Long;  Lu, Shun;  Lu, You;  Zhou, Jianying;  Shi, Yuan-kai 收藏  |  浏览/下载：7/0  |  提交时间：2019/02/25 ALK-positive advanced non-small cell lung cancer  crizotinib  chemotherapy  phase III   Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer 期刊论文 2018, 卷号: 13, 期号: 10, 页码: 1539-1548 作者:  Wu, Yi-Long;  Lu, Shun;  Lu, You;  Zhou, Jianying;  Shi, Yuan-kai 收藏  |  浏览/下载：6/0  |  提交时间：2020/01/03 ALK-positive advanced non-small cell lung cancer  crizotinib  chemotherapy  phase III   Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK plus advanced non-squamous non-small cell lung cancer (NSCLC). 期刊论文 2016, 卷号: 34, 期号: 15 作者:  Lu, Shun;  Mok, Tony;  Lu, You;  Zhou, Jianying;  Shi, Yuankai 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04 Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK plus advanced non-squamous non-small cell lung cancer (NSCLC). 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20 作者:  Lu, Shun;  Mok, Tony;  Lu, You;  Zhou, Jianying;  Shi, Yuankai 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04